Trends in the Cumulative Post-Marketing Reporting Rates of Retinal Vasculitis and/or Retinal Vascular Occlusion and Associated Vision Loss with Brolucizumab

INTRODUCTION: Brolucizumab, a low-molecular weight anti-vascular endothelial growth factor, was approved in the USA in October 2019 for the treatment of neovascular age-related macular degeneration. Following post-marketing reports of vasculitis, including retinal occlusive vasculitis, a safety sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Igwe, Franklin, Lodha, Amit, Ravindran, Arun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834481/
https://www.ncbi.nlm.nih.gov/pubmed/36469211
http://dx.doi.org/10.1007/s40123-022-00617-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834481/
https://www.ncbi.nlm.nih.gov/pubmed/36469211
http://dx.doi.org/10.1007/s40123-022-00617-5

Ejemplares similares